FDA OKs GSK’s Advair HFA
This article was originally published in The Pink Sheet Daily
FDA approved an NDA for GlaxoSmithKline's asthma treatment Advair HFA (salmaterol/fluticasone) on June 8, the agency said
You may also be interested in...
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.